CC
BIOC

Callan Capital’s Biocept, Inc. BIOC Stock Holding History

Callan Capital’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$25K – 62
2016
Q2 		$25K Hold
1
– – 0.01% 67
2016
Q1 		$49K Hold
1
– – 0.02% 61
2015
Q4 		$52K Hold
1
– – 0.02% 63
2015
Q3 		$87K Hold
1
– – 0.05% 61
2015
Q2 		$43K Hold
1
– – 0.01% 69
2015
Q1 		$38K Buy
+1
New +$67.2K 0.01% 67

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Callan Capital's BIOC Position: Q3 2016 in Review

Callan Capital sold out of Biocept, Inc. (BIOC) in Q3 2016, closing a stake of 1 share — an estimated $25K sold.

Callan Capital first reported a position in BIOC in Q1 2015 and held it in 6 quarters. The position peaked at $87K in Q3 2015. 6 funds tracked by Wall St. Rank hold BIOC as of Q3 2016.

  • Callan Capital reported no remaining Biocept, Inc. position as of Q3 2016 after selling out during the quarter.
  • Callan Capital sold 1 Biocept, Inc. share in Q3 2016, an estimated $25K.
  • Callan Capital first reported a position in Biocept, Inc. in Q1 2015 and held it in 6 quarters.
  • Callan Capital's Biocept, Inc. position peaked at $87K in Q3 2015.
  • 6 funds tracked by Wall St. Rank held Biocept, Inc. as of Q3 2016.

Based on Callan Capital's 13F filing for Q3 2016, filed 15 Nov 2016.